Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab mafodotin + venetoclax
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Belantamab mafodotin + venetoclax is a combination therapy being investigated for the treatment of relapsed and refractory multiple myeloma, particularly in patients with t(11;14) translocation. This combination pairs two distinct mechanisms of action: 1. **Belantamab mafodotin** is an antibody-drug conjugate (ADC) consisting of an afucosylated IgG1 monoclonal antibody targeting B-cell maturation antigen (BCMA) conjugated to monomethyl auristatin-F (MMAF), a potent microtubule inhibitor. It works by binding to BCMA on multiple myeloma cells, leading to internalization of the drug complex, release of MMAF, cell cycle arrest, and apoptosis. 2. **Venetoclax** is a selective BCL-2 inhibitor that has shown particular efficacy in multiple myeloma patients with t(11;14) translocation. The combination is being studied to potentially enhance efficacy in treating relapsed/refractory multiple myeloma through complementary mechanisms of action.
- Brand names
- BlenrepVenclextaVenclyxto
- Other names
- belantamab mafodotin-blmfbelamafvenetoclax
02
Targets
BCMA (B-cell maturation antigen)BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on belantamab mafodotin + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab mafodotin + venetoclax.